FOLH1 and pachyonychia congenita: The ability of PSMA PET/CT to detect recurrence at an earlier stage of disease suggests greater opportunities for life-prolonging treatment; however, given the often indolent clinical course of recurrent PC, the potential benefits of earlier, aggressive therapeutic intervention in patients with limited recurrence will need to be weighed carefully against the risk of associated toxicities and quality of life impairment (28).